Courtney Breen

Courtney Breen Analyst Performance

Senior Research Analyst at Sanford C. Bernstein

Courtney Breen is a stock analyst at Sanford C. Bernstein in the healthcare sector, covering 8 publicly traded companies. Over the past year, Courtney Breen has issued 14 stock ratings, including buy and hold recommendations. While full access to Courtney Breen's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Courtney Breen's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
23 Last 2 Years
Buy Recommendations
52.17% 12 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy52.2%12 ratings
Hold47.8%11 ratings
Sell0.0%0 ratings

Out of 23 total stock ratings issued by Courtney Breen at Sanford C. Bernstein, the majority (52.2%) have been Buy recommendations, followed by 47.8% Hold.

Exchange Coverage

ExchangePercentageCount
NYSE
62.5% of companies on NYSE
5 companies
NASDAQ
37.5% of companies on NASDAQ
3 companies

Courtney Breen, an analyst at Sanford C. Bernstein, currently covers 8 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Healthcare
8 companies
100.0%

Courtney Breen of Sanford C. Bernstein specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
4 companies
50.0%
BIOTECHNOLOGY
4 companies
50.0%

Courtney Breen's Ratings History at Sanford C. Bernstein

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Pfizer Inc. stock logo
PFE
Pfizer
11/12/2026Reiterated Rating$29.13$29.00Market Perform
Amgen Inc. stock logo
AMGN
Amgen
11/4/2026Boost Price Target$474.56$400.00Market Perform
AbbVie Inc. stock logo
ABBV
AbbVie
11/2/2026Reiterated Rating$288.31$275.00Market Perform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
11/2/2026Reiterated Rating$170.34$175.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
10/26/2026Reiterated Rating$1,275.50$1,450.00Outperform
Amgen Inc. stock logo
AMGN
Amgen
8/6/2026Boost Price Target$407.83$345.00Market Perform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
7/14/2026Boost Price Target$1,144.83$1,385.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
7/14/2026Boost Price Target$1,185.72$1,385.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
3/10/2026Reiterated Rating$1,002.19Outperform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/11/2026Reiterated Rating$155.13$160.00Outperform
Amgen Inc. stock logo
AMGN
Amgen
1/20/2026Downgrade$328.65$335.00Market Perform
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
12/29/2025Set Price Target$124.72$135.00Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
12/19/2025Reiterated Rating$1,067.63Outperform
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
11/24/2025Boost Price Target$1,058.05$1,300.00Outperform
Pfizer Inc. stock logo
PFE
Pfizer
10/31/2025Reiterated Rating$24.42$30.00Market Perform